Hepatocellular carcinoma (HCC) is a critical global health issue and the third most common cause of cancer-related deaths worldwide. The majority of patients who present HCC are already at an advanced stage and their tumors are unresectable. Sorafenib is a multi-kinase inhibitor of the vascular endothelial growth factor pathway and was recently introduced as a therapy for advanced HCC. Furthermore, studies have shown that oral sorafenib has beneficial effects on survival. However, many patients experience diverse side effects, and some of these are severe. Liver abscess development has not been previously documented to be associated with sorafenib administration in HCC. Here, we report the case of a HCC patient that developed a liver abscess while being treated with sorafenib. (Korean J Gastroenterol 2014;63:47-50) 
INTRODUCTION
HCCs which are richly supplied with blood vessels. 1, 2 Sorafenib is multi-tyrosine kinase inhibitor that targets Raf, vascular endothelial growth factor, platelet-derived growth factor, and c-kit. 3 It is believed that the benefits of sorafenib are due to its anti-proliferative and anti-angiogenic effects. These benefits were demonstrated in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in which sorafenib was found to increase median overall survival from 7.9 to 10.7 months in advanced HCC patients with
Child-Pugh classification A cirrhosis. 4 In addition, in the SHARP trial, drug-related adverse events of any grade were found to occur more significantly among sorafenib than did placebo recipients. Documented adverse events included diarrhea, hand-foot skin reactions, anorexia, alopecia, weight loss, dry skin, abdominal pain, voice changes, and other dermatological events. 4, 5 However, no report has previously linked sorafenib with liver abscess development. Here, we report for the first time a case of liver abscess after sorafenib treatment in a patient with advanced HCC, and we include a review of the literature.
CASE REPORT
A 55-year-old male was admitted to our hospital with symp- (Fig. 2) .
Sorafenib was immediately stopped, and broad spectrum intravenous antibiotic treatment (cefotaxime and metronidazole) was started for the liver abscess. We did not perform percutaneous catheter drainage or needle aspiration for the liver abscess. The fever promptly subsided, and, subsequently, Peptoniphilus asaccharolyticus was cultured from the blood.
After 20 days of antibiotic treatment, his symptoms were slightly improved, and he was discharged. Laboratory data at discharge were as follows: total bilirubin, 6.4 mg/dL; ALP, However, one week after discharge, he was readmitted due to poor oral intake. A CT scan performed at the time showed the air densities had disappeared, but that the HCC had progressed (Fig. 3) . He was subsequently discharged to a hospice center where he succumbed to liver failure.
DISCUSSION
Sorafenib has been reported to be well-tolerated with manageable side-effects, the most common of which are hand-foot skin reaction, diarrhea, alopecia, fatigue, rash or desquamation, and hypertension. 4 ,5 However, we found that a liver abscess associated with tumor necrosis and gas formation developed after only 4 days of sorafenib use in an advanced HCC patient. Moreover, this link between sorafenib and liver abscess development has not been previously reported.
Liver abscesss can be caused by bacteria, parasites, and fungi, but the most common organisms to cause them are Klebsiella pneumoniae and Escherichia coli. 6 In our case, Peptoniphilus asaccharolyticus (a gram positive anaerobic cocci) was cultured from the blood, and it is not a common pathogen in liver abscess. In 1998, it was reported that the predominant anaerobes in causes of liver abscesses were Peprostreptococcus spp. (18 isolates) that included P. micros (7), P. prevotii (4), P. anaerobius (3), P. magnus (2) and P. asaccharolyticus (2). On the other hand, liver abscess development after specific treatments for HCC has been reported extensively, for example, after radiofrequency ablation or embolization. Reported incidences of liver abscess formation after transcatheter arterial chemoembolization (TACE) ranged from 0% to 3.3%, 9-11 and after radiofrequency ablation (RFA) range from 1.5% to 2.4%. [11] [12] [13] Gas-forming liver abscess development is even rarer and relatively few case reports have been issued on the topic. These abscesses are usually encountered after RFA, and are believed to be caused by bacterial contamination of ablated regions. 11 However, the mechanism involved has not been properly established. The pathogenic mechanism of liver abscess formation after TACE has been linked to biloma formation and biliary tract infection.
The pathophysiology of biloma formation involves ischemic injury to the peribiliary capillary plexus, which is supplied by branches of the hepatic artery. As a result, the integrity of the biliary tree is disrupted, and biloma formation ensues. 
